HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report)'s stock price gapped down before the market opened on Monday . The stock had previously closed at $14.38, but opened at $12.79. HUTCHMED shares last traded at $12.68, with a volume of 9,907 shares trading hands.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded HUTCHMED from a "hold" rating to a "buy" rating in a research note on Friday, March 21st.
Read Our Latest Report on HUTCHMED
HUTCHMED Stock Performance
The company's 50 day simple moving average is $14.75 and its 200-day simple moving average is $16.16. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Public Employees Retirement System of Ohio bought a new position in shares of HUTCHMED during the third quarter valued at about $35,000. Barclays PLC boosted its position in HUTCHMED by 1,483.6% during the 4th quarter. Barclays PLC now owns 2,407 shares of the company's stock valued at $35,000 after buying an additional 2,255 shares during the period. Blue Trust Inc. grew its stake in shares of HUTCHMED by 99.9% in the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock worth $102,000 after purchasing an additional 3,532 shares during the last quarter. Summit Trail Advisors LLC lifted its holdings in HUTCHMED by 14.4% in the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock worth $189,000 after buying an additional 1,647 shares during the period. Finally, OLD Mission Capital LLC bought a new stake in HUTCHMED in the fourth quarter valued at $230,000. 8.82% of the stock is currently owned by institutional investors.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Read More
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
